FORUS Therapeutics is pleased to announce that US-authorized BESREMi® (ropeginterferon alfa-2b-njft), is now available in Canada, via Exceptional Importation.
Please note, BESREMi®’s active ingredient, ropeginterferon alfa-2b-njft, has not been reviewed under Health Canada’s standard drug review process and is not found in any other drug previously authorized for sale in Canada.
Please refer to the below for important information:
Materials for Healthcare Professionals
Materials for Patients
BESREMi® Packaging Images
- Carton Contents
- Carton Label
- BESREMi® Single Use Pre-Filled Syringe with Needle Attached
- BESREMi® Syringe Label
Note: The Ontario PIN for BESREMi® is 09858357.
At FORUS, we are committed to patient safety. To report a side effect/adverse reaction or for medical questions or product quality complaints, please contact us:
Phone: 1-866-542-7500
Monday to Friday, 9 a.m. – 5 p.m. (EST), excluding holidays
BESREMi® is a registered trademark of PharmaEssentia Corporation used under license by FORUS Therapeutics Inc. All rights reserved.